Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Venous Thromboembolism

Venous Thromboembolism

Part of Embolism and Thrombosis

13 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Venous Thromboembolism

84 trials tracked for Venous Thromboembolism: 31 in phase 3 or 4 and 14 with published results. The most-cited published study has 1045 citations.

84Trials tracked
31Phase 3 & 4
0Recruiting
14With published results
Phase distribution
Phase 4 9 Phase 3 22 Phase 2 20 Phase 1 5 Other / NA 28
  1. Phase 3 Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer Completed · 1,045 cited
  2. Phase 3 Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism) Completed · 771 cited
  3. Phase 3 Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism Completed · 581 cited
  4. Phase 3 EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis Completed · 321 cited
  5. Phase 3 Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE) Completed · 154 cited
  6. Phase 3 Safety of Dabigatran Etexilate in Blood Clot Prevention in Children Completed · 93 cited
Show 44 more trials
  1. Phase 3 Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis Completed · 86 cited
  2. Phase 3 PROSPER: PostpaRtum PrOphylaxiS for PE Randomized Control Trial Pilot Completed · 83 cited
  3. Phase 4 Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial Completed · 82 cited
  4. Phase 4 Dalteparin for Primary Venous Thromboembolism (VTE) Prophylaxis in Pancreatic Cancer Patients Completed · 63 cited
  5. Phase 4 Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism Completed · 37 cited
  6. Phase 3 Prospective Study on Preoperative Versus Postoperative Venous Thromboprophylaxis in Patients Undergoing Major Colorectal Surgery Completed · 36 cited
  7. Phase 4 Apixaban for Primary Prevention of Venous Thromboembolism in Patients With Multiple Myeloma Completed · 15 cited
  8. Phase 4 Evaluation of Venous Thromboembolism Prevention in High-Risk Trauma Patients Completed · 8 cited
  9. Phase 4 Aspirin for Prevention of Venous Thromboembolism Among Ovarian Cancer Patients Receiving Neoadjuvant Chemotherapy Completed
  10. Phase 4 Use of Tranexamic Acid in Reduction Mammoplasty Completed
  11. Phase 4 Apixaban for the Acute Treatment of Venous Thromboembolism in Children Completed
  12. Phase 4 Fondaparinux in Critically Ill Patients With Renal Failure Completed
  13. Phase 3 A Different Approach to Preventing Thrombosis Completed
  14. Phase 3 RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding Completed
  15. Phase 3 Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thromboembolism (DVT) and Pulmonary Embolism (PE). A Study of BAY59-7939 in the Prevention of Venous Thrombo Embolism (VTE) in Subjects Undergoing Elective Total Knee Replacement. Completed
  16. Phase 3 Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study). Completed
  17. Phase 3 A Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty Completed
  18. Phase 3 Twice-daily Oral Direct Thrombin Inhibitor Dabigatran Etexilate in the Long Term Prevention of Recurrent Symptomatic VTE Completed
  19. Phase 3 A Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty Completed
  20. Phase 3 Dabigatran Etexilate Compared With Enoxaparin in Prevention of Venous Thromboembolism (VTE) Following Total Hip Arthroplasty Completed
  21. Phase 3 Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study Completed
  22. Phase 3 Venous Thromboembolic Event (VTE) Prophylaxis in Medically Ill Patients Completed
  23. Phase 3 The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients Completed
  24. Phase 3 Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Hip Fracture Surgery Completed
  25. Phase 3 Safety and Pharmacokinetics Study of DU-176b Administered to Patients With Severe Renal Impairment Undergoing Orthopedic Surgery of The Lower Limbs Completed
  26. Phase 2 Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma Completed
  27. Phase 2 Apixaban vs Enoxaparin Following Microsurgical Breast Reconstruction-An RCT Completed
  28. Phase 2 Prothrombin Times Outside the Therapeutic Range in Otherwise Stable Patients Completed
  29. Phase 2 Fixed Versus Weight-Based Enoxaparin Dosing in Thoracic Surgery Patients Completed
  30. Phase 2 A Trial to Learn How Well REGN7508 Works for Preventing Blood Clots After a Knee Replacement in Adult Participants Completed
  31. Phase 2 Safety and Tolerability of Dabigatran Etexilate Solution in Children 1 to < 12 Years of Age Completed
  32. Phase 2 BIBR 1048 Dose Range Finding Study in Prevention of Venous Thromboembolism in Patients With Primary Elective Total Hip or Knee Replacement Surgery Completed
  33. Phase 2 Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients Completed
  34. Phase 2 Minimization of Bleeding Related Adverse Drug Events in Plastic & Reconstructive Surgery Completed
  35. Phase 2 Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy Completed
  36. Phase 2 Tolerability , PK/PD and Safety of Dabigatran Etexilate Oral Liquid Formulation in Children < 1 Year of Age Completed
  37. Phase 2 A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty Completed
  38. Phase 2 A Phase 2b Study of DU-176b, Prevention of Venous Thromboembolism in Patients After Total Knee Arthroplasty Completed
  39. Phase 2 Safety and Tolerability of Dabigatran Etexilate in Adolescents Completed
  40. Phase 2 EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis Completed
  41. Phase 2 A Trial to Learn How Well REGN9933 Works for Preventing Blood Clots After Knee Replacement Surgery in Adult Participants Completed
  42. Phase 2 Enoxaparin Metabolism in Reconstructive Surgery Patients Completed
  43. Phase 2 Efficacy of RIvaroxaban for Prevention of Venous Thromboembolism After Knee Arthroscopy Completed
  44. Phase 2 Odiparcil For The Prevention Of Venous Thromboembolism Completed

Showing the 50 most-cited and recently-updated of 84 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Venous Thromboembolism: what the trials found

Clinical trials have evaluated several anticoagulants for the management of venous thromboembolism (VTE). Full-dose unfractionated heparin was found to result in significantly fewer venous or arterial thrombotic events compared to standard-dose prophylactic anticoagulation (p=0.028) 4. However, there was no statistically significant difference between full-dose and standard-dose prophylaxis regarding clinically evident venous or arterial thrombotic events (p=0.087) 4.

Several direct oral anticoagulants (DOACs) have been evaluated in various settings. Apixaban has been studied across multiple trials [6, 7, 9, 13, 15, 22], with one study showing a low incidence of major and clinically relevant non-major bleeding (1.3% vs 1.4%) and similar rates of recurrent VTE and mortality (2.6% vs 2.7%) 9. Rivaroxaban was shown to have no reported cases of symptomatic recurrent VTE during the 30-day post-study treatment period 16. Dabigatran etexilate demonstrated a significant difference in its composite primary endpoint compared to the control group (p=0.0001) with no significant difference in all-cause mortality (p=0.9976) 17, and showed high event-free probabilities for VTE recurrence at 6 and 12 months 18.

Other interventions include Dalteparin [5, 20], Fondaparinux 12, and Tranexamic acid 10. In a study of heparin, no significant difference was found in postoperative VTE within 48 hours (p=0.72) or bleeding complications (p=0.36), though a significant difference was noted in postoperative thrombocytopenia (p=0.03) 21.

The use of anti-platelet therapy versus no anti-platelet therapy did not show a statistically significant difference in the occurrence of venous or arterial thrombotic events (p=0.90) 4.

Recent results — preliminary, needs further review

  • REGN7508 showed a 7.1% rate of confirmed, adjudicated VTE compared to 17.2% in the comparison group 1.
  • A new-prescription alert system was evaluated; approximately 29.84% of DOAC alerts were addressed within 7 days 3.

For the clinician treating this condition

  • Full-dose unfractionated heparin is associated with fewer total venous or arterial thrombotic events compared to standard-dose prophylaxis, though this difference was not statistically significant for clinically evident events.
  • DOACs such as Apixaban, Rivaroxaban, and Dabigatran etexilate have been extensively studied; Rivaroxaban showed no symptomatic recurrent VTE in a 30-day post-treatment window 16, and Dabigatran etexilate showed high event-free probabilities for VTE recurrence at 6 and 12 months 18.
  • Anti-platelet therapy did not show a statistically significant difference over no anti-platelet therapy regarding the incidence of venous or arterial thrombotic events.

AI synthesis of 10 cited trials, updated Jun 23, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Retrievable IVC filters in lung transplant recipients show 66% retrieval rate with low complications
Radiology & Imaging Cohort
Retrievable IVC filters in lung transplant recipients show 66% retrieval rate with low complications Study examines safety and retrieval of blood clot filters in lung transplant patients
A retrospective single-center cohort of 95 lung transplant recipients who received retrievable IVC filters for venous thromboembolism found …
Doctors successfully removed clot-catching filters from two-thirds of lung transplant patients, with the procedure taking just eight minutes…
Frontiers Apr 3, 2026

Research across Embolism and Thrombosis

Related studies from across the Embolism and Thrombosis family.

Specific reversal agents offer high-affinity neutralization but face cost and access barriers in thromboembolism management
Cardiology Sys. Review
Specific reversal agents offer high-affinity neutralization but face cost and access barriers in thromboembolism management New Options and Challenges for Reversing Blood Clot Treatments
This systematic review evaluates procoagulant strategies including specific reversal agents like idarucizumab and non-specific options for t…
Doctors are evaluating specific and non-specific agents to safely reverse the effects of anticoagulant medications in patients with blood cl…
Frontiers Jun 25, 2026
DOACs reduce thromboembolic events in pediatric patients compared to standard anticoagulation
Infectious Disease Meta-analysis
DOACs reduce thromboembolic events in pediatric patients compared to standard anticoagulation A Pill Form of Blood Thinner May Be Safer for Kids Than Standard Shots
A meta-analysis of 2,002 pediatric patients found direct oral anticoagulants (DOACs) significantly reduced thromboembolic event recurrence (…
New oral blood thinners cut dangerous blood clot recurrences in half for children without increasing bleeding risks compared to standard sho…
Frontiers Apr 13, 2026

Questions about Venous Thromboembolism

Does having asthma increase my odds of developing venous thromboembolism or deep vein thrombosis?

Yes, asthma is linked to higher odds of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE).

Full answer →
What factors predict a recurrence of venous thromboembolism or bleeding in adult cancer patients?

In adult cancer patients, prior VTE, poor performance status, advanced cancer, and certain tumor sites (lung, pancreas, hepatobiliary, genitourinary) predict higher recurrence risk; elevated biomarkers like growth differentiation factor-15 also raise risk.

Full answer →